Abstract
Acute Myeloid Leukemia (AML) is a genetically, epigenetically, and clinically heterogeneous group of clonal Bone Marrow (BM) diseases. Since its treatment has not undergone major changes in the last decades, long-term disease outcomes have not shown significant improvement over the years. Furthermore, the therapies currently used have high systemic toxicity, thus making it necessary to st…